1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Acura Pharmaceuticals, Inc.

Acura Pharmaceuticals, Inc.

ACUR
Acura Pharmaceuticals, Inc.US flagOther OTC
0.00
USD
- -
- -
13,200.00Market Cap
2009 Y
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
TTM
Revenue per Share
0.42
0.35
2.15
- -
0.01
0.08
0.8
0.38
0.19
0.02
0.1
0.11
0.03
0.03
Basic EPS, GAAP
-1.72
-1.35
1.09
-1.02
-1.46
-1.35
-0.46
-0.62
-0.36
-0.18
-0.14
-0.04
-0.02
-0.02
Free Cash Flow per Basic Share
-0.57
-0.69
1.28
-0.76
-1.43
-1.35
-0.36
-0.47
-0.28
-0.18
-0.02
-0.02
-0.01
-0.01
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-35.14
-35.67
-34.22
-35.22
-36.49
-37.04
-34.01
-31.56
-23.91
-18.16
-14.51
-12.04
-6.86
-6.88
Tangible Book Value per Share
3.26
2.59
3.86
2.91
1.88
0.33
0.58
-0.02
-0.08
-0.22
-0.21
-0.18
- -
- -
Basic Weighted Avg Shares
9
9
10
10
10
10
11
12
16
21
27
32
57
57
Sales/Revenue/Turnover
4
3
20
- -
- -
1
9
4
3
- -
3
4
2
2
Operating Margin (%)
-352.02
-384.29
51.47
- -
-11,455.28
-1,624.37
-46.59
-146.89
-176.16
-954.88
-27.29
-21.23
-77.67
-77.67
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-16
-13
10
-10
-14
-13
-5
-7
-6
-4
-4
-1
-1
-1
Effective Tax Rate (%)
- -
- -
1.4
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-412.91
-383.78
50.74
- -
-11,301.63
-1,758.85
-58.1
-165.5
-191.57
-937.07
-142.04
-33.84
-56.24
-56.24
Working Capital
29
23
36
27
26
10
11
2
-2
-1
- -
-6
- -
- -
LT Debt
- -
- -
- -
- -
10
8
5
3
- -
4
6
- -
- -
- -
Total Equity
30
24
37
28
18
5
8
1
- -
-4
-5
-6
- -
- -
Return on Invested Capital (%)
- -
- -
34.02
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
-3.14
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-0.23
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Jun'21
Sep'21
Dec'21
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
65
65
65
Market Capitalization
24
26
28

Working Capital

FRC

•

in mil. unless spec.
Jun'21
Sep'21
Dec'21
Total Current Assets
1
1
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
1
1
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
1
1
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1,298.61%
2,629.27%
-103.02%
Free Cash Flow
-19.6%
-19.6%
3.2%
Net Income, GAAP
-32.09%
-30.49%
-27.24%
Sales/Revenue/Turnover
- -
81.29%
-56.22%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2019
- -
- -
1
1
3
2020
1
1
- -
1
4
2021
1
1
- -
- -
2

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2019
-0.04
-0.15
0.01
- -
-0.14
2020
-0.02
0.01
-0.02
- -
-0.04
2021
-0.01
-0.01
- -
- -
-0.02

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2019
- -
- -
- -
- -
- -
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -

Company Description

MCPAPIChat
CEO
Robert Jones
Full Time Employees
9
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
616 N. North Court Palatine IL United States of America 60067
IPO Date
Mar 28, 1986
CIK
0000786947
Website
acurapharm.com
Similar Companies
MJ Holdings, Inc. (MJNE)
Jushi Holdings Inc. (JUSHF)
Silo Wellness Inc. (SILFF)
Camurus AB (publ) (CAMX.ST)
Incannex Healthcare Limited (IHL.AX)
CordovaCann Corp. (CDVA.CN)
Business
Acura Pharmaceuticals, Inc. (ACUR) develops and commercializes proprietary drug delivery technologies designed to deter medication abuse, misuse, and overdose, including its LIMITx, Aversion, and Impede platforms; LIMITx retards active drug release upon intentional or accidental ingestion of multiple tablets by neutralizing stomach acid with buffers while delivering normal therapeutic levels from single doses, as in lead candidate LTX-03 (hydrocodone bitartrate/acetaminophen); Aversion incorporates gelling agents and nasal irritants to thwart snorting and injection abuse, powering the FDA-approved OXAYDO tablets (oxycodone HCl, CII) in 5mg and 7.5mg strengths licensed to Zyla Life Sciences; and Impede resists pseudoephedrine extraction for methamphetamine conversion, featured in Nexafed (pseudoephedrine HCl 30mg) and Nexafed Sinus Pressure + Pain (pseudoephedrine HCl/acetaminophen 30/325mg) marketed by MainPointe Pharmaceuticals in the United States and Canada. Founded in 1935 and headquartered in Palatine, Illinois, the company targets the U.S. pharmaceutical market, focusing on opioid analgesics, pseudoephedrine products, and abuse-deterrent formulations for prescribers, pharmacies, and patients seeking safer medication options. In recent developments, Acura has secured multiple loans from Abuse Deterrent Pharma LLC (AD Pharma), which controls about 65% of its common stock, pushing total principal owed to approximately $9 million as of October 2025 with 5.25% interest maturing variably through early 2026, amid ongoing operational funding needs that risk scaling back, furloughs, or termination absent further capital; LTX-03 U.S. commercialization rights are exclusively licensed to AD Pharma, with the latest amendment (effective May 2025) extending the FDA New Drug Application acceptance deadline to December 31, 2025, while the FDA requires additional data plans for lower strengths.

Company News

MCPAPIChat

  • defenseworld.net

    Acura Pharmaceuticals (OTCMKTS:ACUR) Shares Pass Above Two Hundred Day Moving Average – Should You Sell?

  • globenewswire.com

    Acura Pharmaceuticals Announces Second Quarter 2021 Financial Results